Today: 1 March 2026
Subscribe
Browse Category

NYSE:PFE 22 June 2025 - 27 October 2025

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer shares traded near $24.76 on Oct. 24, up about 9% from their 52-week low but still down for the year. The stock jumped over 6% in late September after Pfizer reached a deal with the Trump administration to cut Medicaid drug prices, easing regulatory risk. Pfizer reports Q3 results Nov. 4, with analysts expecting lower earnings due to falling COVID product sales.
27 October 2025
··
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Wall Street Explodes: Dow Jones Jumps 400 Points as Inflation Cools – Tech Stocks Lead, Fed Cuts Expected

U.S. stocks closed at record highs Friday, with the Dow up 400 points and the S&P 500 and Nasdaq also reaching new peaks. Tech and chip stocks led gains—AMD surged 6.5%, Nvidia 4.2%. September inflation rose just 0.3%, below forecasts, boosting bets on a Fed rate cut at the Oct. 29 meeting. Energy and industrial shares lagged, while a partial government shutdown continued.
24 October 2025
·············
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer shares surged 15% from $23.6 to $27.2 after announcing a Medicaid pricing deal with the Trump administration and agreeing to buy obesity drug developer Metsera for up to $7.3 billion. Q2 revenue rose 10% to $14.7 billion, beating estimates. Pfizer trimmed its dividend but still yields 6–7%. Analysts raised price targets to $29–30, citing the pricing pact and new drug prospects.
19 October 2025
·
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

The Nasdaq closed at 22,679.98 Friday, up 117 points, capping a volatile week near record highs. Nvidia shares retreated after hitting records, while AMD jumped 34% on an OpenAI chip deal. The KBW Regional Bank Index rebounded after sharp losses as banks addressed loan and fraud concerns. The VIX spiked to a six-month high before easing, with traders bracing for volatility ahead of major tech earnings and a delayed U.S. inflation report.
18 October 2025
·········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock Soars After Trump’s Drug Deal and Obesity Bet – Is This the Start of a Comeback?

Pfizer shares surged 15% in late September 2025, jumping from $23.60 to $27.20 after a drug-pricing deal with the Trump administration slashed Medicaid prices and a $7.3 billion acquisition of obesity-drug maker Metsera. The stock hovered near $27–$28 as of Oct. 6, near its 52-week high. Pfizer’s dividend yield rose above 7% after earlier declines. Q2 revenue climbed 10% year-over-year to $14.7 billion.
6 October 2025
·
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

All three major U.S. indexes closed at record highs on Oct. 1, with the S&P 500 topping 6,700 for the first time. ADP reported U.S. private payrolls fell by 32,000 in September, fueling bets on two Fed rate cuts by year-end. The 10-year Treasury yield dropped to 4.10%, gold hit a record near $3,895, and healthcare stocks surged after a Trump–Pfizer price deal. Lithium Americas soared 23% after a U.S. government investment.
2 October 2025
······
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer’s Stock Surges: How Trump’s Pricing Deal and Big Drug Bets Sparked the Rally

Pfizer shares surged 15% from Sept. 26 to Oct. 1, closing at $27.21 after a major drug-pricing deal with the Trump administration. The agreement, announced Sept. 30, ties U.S. Medicaid prices to those in other wealthy countries in exchange for tariff relief. Pfizer also agreed to buy obesity-drug developer Metsera for $4.9 billion. Market cap stands near $155 billion, with a dividend yield around 6%.
2 October 2025
···
Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

Market Record Rally Amid Shutdown: A Deep Dive into U.S. Stock Performance on 1 October 2025

U.S. stocks closed at record highs despite a partial government shutdown, with the S&P 500 up 0.34% to 6,711.20 and the Dow rising 0.09% to 46,441.10. Health-care shares jumped after Pfizer and the White House struck a drug price deal, sending Biogen up 10.9%. The ADP report showed private-sector jobs fell by 32,000 in September, but investors bet on Fed rate cuts.
1 October 2025
·····
Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

Trump Unveils ‘TrumpRx’ Plan with Pfizer Deal to Slash Drug Prices

President Trump will announce “TrumpRx,” a federal website allowing Americans to buy discounted prescription drugs directly. The White House secured a deal with Pfizer to cut U.S. prices on several medications and invest $70 billion in domestic research. Drugmakers responded with new direct-sales programs and pledged $500 billion in U.S. investments. Some experts warn price controls could limit innovation and shift higher costs overseas.
30 September 2025
·
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer (PFE) Stock Soars on Trump’s Drug-Price Pact and $7.3B Weight-Loss Deal

Pfizer shares closed near a 52-week low at $24.40 on Sept. 30, 2025, despite Q2 revenue of $14.7 billion and adjusted EPS of $0.78, both above expectations. The company raised full-year EPS guidance and announced a $4.9 billion deal to acquire obesity drugmaker Metsera. President Trump unveiled a pact for Pfizer to cut U.S. drug prices and sell through a new TrumpRx site. FDA approved Pfizer’s updated COVID-19 vaccine for high-risk groups.
30 September 2025
··
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

The Nasdaq snapped a three-week win streak despite a Friday rebound, closing at 22,484, down 0.6% for the week. Trump announced new tariffs on trucks, pharma, and furniture, sending Paccar up 5.2% and RH down 4%. Nvidia signaled a $100 billion OpenAI investment, fueling a semiconductor rally. Core inflation matched forecasts at 2.7% year-on-year in August.
27 September 2025
··········
Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer Stock 2025: 7% Dividend, Obesity Gamble, and Wall Street’s Verdict

Pfizer shares closed at $23.60 on Sept. 25, 2025, down 9% year-to-date and 18% from a year ago, near the bottom of their 52-week range. The dividend yield has risen above 7% as the stock slumped. In September, Pfizer announced a $7.3 billion acquisition of Metsera and reported strong Phase 3 results for a new COVID-19 vaccine. A key court hearing on Depo-Provera lawsuits is set for Sept. 29.
26 September 2025
···
Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

Biotech, Pharma, and Health Breakthroughs You Missed on August 17–18, 2025

The FDA approved Tonix’s Tonmya as the first new fibromyalgia drug in over 15 years. Novo Nordisk’s Wegovy received accelerated FDA approval for MASH, becoming the first GLP-1 therapy cleared for the liver disease. Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, marking another setback after its $5.4 billion Global Blood Therapeutics acquisition. Eli Lilly announced a $1.3 billion AI drug partnership with Superluminal.
18 August 2025
·····
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Miracle Drugs, Mega Mergers & Outbreak Alerts – Biotech & Health News Roundup (Aug 15–16, 2025)

Wegovy became the first GLP-1 therapy approved by the FDA for MASH, affecting about 5% of U.S. adults. Tonix’s Tonmya was cleared for fibromyalgia, the first new therapy in 15 years. Pfizer’s inclacumab failed a key sickle cell trial, and Oxbryta was withdrawn. BioNTech agreed to acquire CureVac in a $1.25 billion all-stock deal.
16 August 2025
··········
Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

Breakthrough Cures, FDA Shake-Ups & Pharma Mega‑Deals: Global Health News Roundup (Aug 9–10, 2025)

China researchers reported a hydrogel “smart” wound dressing that closed 90% of diabetic ulcers in mice within 12 days by delivering microRNA vesicles. The FDA approved Boehringer Ingelheim’s Hernexeos for advanced non-squamous NSCLC, with 75% of treated patients seeing tumors shrink or disappear. U.S. IV saline shortages ended as Baxter’s North Carolina plant resumed production after hurricane damage.
10 August 2025
······
Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Top 100 Global Biotechnology Companies Revolutionizing Science and Health

Pfizer and BioNTech co-developed Comirnaty, the first FDA-approved mRNA COVID-19 vaccine. Roche leads in oncology and diagnostics, while Moderna advanced mRNA vaccines for COVID-19 and other diseases. Illumina dominates DNA sequencing, and CRISPR Therapeutics develops gene-editing therapies for sickle cell disease.
22 June 2025
···········
1 … 7 8 9
Go toTop